Cardiotrophin-1 (CT-1) holds potent anti-inflammatory, cytoprotective, and anti-apoptotic effects in the liver, kidneys, and heart. In the present study, the role of endogenous CT-1 and the effect of exogenous CT-1 were evaluated in experimental ulcerative colitis. Colitis was induced in CT-1 knockout and wild-type (WT) mice by administration of dextran sulphate sodium (DSS) in the drinking water during 7 days. CT-1 knockout mice showed higher colon damage and disease severity than WT mice. In addition, CT-1 (200 µg/kg/day, iv) or vehicle (as control) was administered during 3 days to WT, colitic mice, starting on day 4 after initiation of DSS. Disease activity index (DAI), inflammatory markers (tumor necrosis factor α (TNF-α), INFγ, IL-17, IL-10, inducible nitric oxide synthase (iNOS)), colon damage, apoptosis (cleaved caspase 3), nuclear factor κB (NFκB) and STAT-3 activation, and bacterial translocation were measured. Compared with mice treated with DSS, mice also treated with exogenous CT-1 showed lower colon damage, DAI, plasma levels of TNFα, colon expression of TNF-α, INFγ, IL-17, iNOS and cleaved caspase 3, higher NFκB and signal transducer and activator of transcription 3 (STAT3) pathways activation, and absence of bacterial translocation. We conclude that endogenous CT-1 plays a role in the defense and repair response of the colon against ulcerative lesions through an anti-inflammatory and anti-apoptotic effect. Supplementation with exogenous CT-1 ameliorates disease symptoms, which opens a potentially new therapeutic strategy for ulcerative colitis.
Skip Nav Destination
Article navigation
May 2018
-
Cover Image
Cover Image
Depiction of a macrophage. In issue 9 of Clinical science, Liu et al. discuss the role of miRNAs in alveolar macrophage activation; for details see pages 943–958.
Research Article|
May 23 2018
Cardiotrophin-1 attenuates experimental colitis in mice
Vanessa Prieto-Vicente;
Vanessa Prieto-Vicente
*
1Department of Gastroenterology, University Hospital of Salamanca, Salamanca 37007, Spain
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
Search for other works by this author on:
Ana I. Sánchez-Garrido;
Ana I. Sánchez-Garrido
*
1Department of Gastroenterology, University Hospital of Salamanca, Salamanca 37007, Spain
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
Search for other works by this author on:
Víctor Blanco-Gozalo;
Víctor Blanco-Gozalo
*
3Bio-inRen S.L. School of Medicine, Campus Miguel de Unamuno, Salamanca 37007, Spain
Search for other works by this author on:
Miguel Arévalo;
Miguel Arévalo
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
4Department of Human Anatomy and Histology, University of Salamanca, Salamanca 37007, Spain
Search for other works by this author on:
Enrique García-Sánchez;
Enrique García-Sánchez
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
5Department of Preventive Medicine, Public Health and Medical Microbiology, University of Salamanca, Salamanca 37007, Spain
Search for other works by this author on:
Daniel López-Montañés;
Daniel López-Montañés
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
3Bio-inRen S.L. School of Medicine, Campus Miguel de Unamuno, Salamanca 37007, Spain
Search for other works by this author on:
Yaremi Quiros;
Yaremi Quiros
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
3Bio-inRen S.L. School of Medicine, Campus Miguel de Unamuno, Salamanca 37007, Spain
Search for other works by this author on:
Francisco J. López-Hernández;
Francisco J. López-Hernández
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
6Department of Physiology and Pharmacology, University of Salamanca, Salamanca 37007, Spain
Search for other works by this author on:
Antonio Rodríguez-Pérez;
Antonio Rodríguez-Pérez
1Department of Gastroenterology, University Hospital of Salamanca, Salamanca 37007, Spain
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
Search for other works by this author on:
José M. López-Novoa
2Biomedical Research Institute of Salamanca (IBSAL), Salamanca 37007, Spain
6Department of Physiology and Pharmacology, University of Salamanca, Salamanca 37007, Spain
Correspondence: José M. López-Novoa ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
November 10 2017
Revision Received:
March 09 2018
Accepted:
March 12 2018
Accepted Manuscript online:
March 23 2018
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (9): 985–1001.
Article history
Received:
November 10 2017
Revision Received:
March 09 2018
Accepted:
March 12 2018
Accepted Manuscript online:
March 23 2018
Connected Content
A commentary has been published:
Potential clinical treatment of colitis with cardiotrophin-1
Citation
Vanessa Prieto-Vicente, Ana I. Sánchez-Garrido, Víctor Blanco-Gozalo, Miguel Arévalo, Enrique García-Sánchez, Daniel López-Montañés, Yaremi Quiros, Francisco J. López-Hernández, Antonio Rodríguez-Pérez, José M. López-Novoa; Cardiotrophin-1 attenuates experimental colitis in mice. Clin Sci (Lond) 16 May 2018; 132 (9): 985–1001. doi: https://doi.org/10.1042/CS20171513
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.